T1	Participants 31 89	thrombocytopenic subjects with hepatitis C virus infection
T2	Participants 207 256	Hepatitis C virus (HCV)-related thrombocytopenia.
T3	Participants 311 390	thrombocytopenic patients (n = 1463, age ≥ 18 years) with chronic HCV infection
T4	Participants 418 490	target platelet count of > 90 × 10(9) /L following eltrombopag treatment
T5	Participants 1749 1777	HCV-related thrombocytopenia
T6	Participants 1965 1985	liver decompensation
